Cenix BioScience

The company was founded in 1999 to provide high-throughput target discovery and validation services for academic and industry partners.

NEW YORK (GenomeWeb) – Contract research organization Cenix BioScience this week announced a research framework agreement with metabolite services and biomarker firm Metanomics Health.

NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.

As part of an ongoing effort to support research into rare and neglected diseases, Cenix BioScience announced last week that it has struck a research agreement with the Children's Tumor Foundation, a non-profit organization focused on developing treatments for neurofibromatosis.

Cytoo will coordinate a new European consortium that will rely on the firm's micropattern array platform to develop a high-throughput approach to RNAi screening in cultured cells.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Cytoo will coordinate a project announced on Monday that aims to combine high-throughput applications of RNAi with Cytoo's new cell normalization technology.

Cenix BioScience announced this week that it has signed a research agreement with Sygnis Bioscience.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Becton Dickinson announced the latest round of winners of its BD Biosciences Research Grant Program. Winners will receive $10,000 worth of research reagents for their projects.

The deal represents an expansion of an ongoing partnership between Cenix and Janssen focused on improving in vivo siRNA-based target validation methodologies in the central nervous system.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.